Enhertu Is First ADC Approved For Tumor-Agnostic Indication
The US Food and Drug Administration approved Daiichi Sankyo/AstraZeneca’s Enhertu for metastatic HER2-positive solid tumors.
The US Food and Drug Administration approved Daiichi Sankyo/AstraZeneca’s Enhertu for metastatic HER2-positive solid tumors.